



FOR IMMEDIATE RELEASE

BirchBioMed welcomes Dr. Carlos Roberto Camozzi as Chief Medical Officer

Leader in strategic drug development, therapeutic options, and market access

VANCOUVER, British Columbia – March 2023: BirchBioMed, a clinical-stage biomedical company focused on evaluation, development and commercialization of anti-scarring drugs and treatments, autoimmune therapeutics and novel strategies for transplantation, is pleased to welcome Dr. Carlos Roberto Camozzi, M.D., Ph.D., as Chief Medical Officer.

Prior to joining BirchBioMed, Dr. Camozzi founded CRC-Management Consulting GmbH in 2018, advising and consulting C-suite executives in the pharmaceutical industry to bring innovative, safe, and effective therapeutic options to patients suffering rare diseases and those with high unmet medical needs.

He has successfully led several regulatory interactions, consultations, submissions and approvals, with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), of several pre-INDs and INDs, CTAs and IRBs/ECs, Orphan Drug Applications (ODA) and Designations (ODD), Paediatric Investigational Plans (PIP), successful review approaches (i.e. priority review, breakthrough therapy, accelerated approval, fast track, conditional approval, exceptional circumstances), and Marketing Authorisations Applications (MAA).

Dr. Camozzi's outstanding clinical and regulatory achievements include FDA approval of Carbaglu™ for the treatment of NAGS deficiency and the well-known EMA re-assessment and first ever approval of a gene-therapy (Glybera™) in the western world.

He most recently served as Medical Director and member of the Executive Committee of NLS Pharmaceuticals, Medical Director / Head of Medical Affairs Department, Development Projects Coordinator, for Orphan Europe (member of the Recordati Group), a pioneer in the development and commercialisation of orphan drugs, Scientific Strategy Director, Division of Molecular Pathology - Basel University Hospital, and Chief Medical Officer for Amsterdam Molecular Therapeutics (Euronext: AMT).

Dr. Camozzi has more than 40 years experience in the healthcare industry, having received his medical degree from School of Medicine, National University of Buenos Aires, his PhD in Clinical Chemistry, also from the National University of Buenos Aires, and holds degrees in Paediatrics, Neonatology, Clinical Pharmacology and Neuropsychiatry.

“Dr. Camozzi appointment as our Chief Medical Officer comes at a pivotal point in our clinical development,” said BirchBioMed Chairman & CEO Mark Miller. “As our Chief Medical Officer, he brings a wealth of experience in investigation and development of pre-clinical and clinical programs, and his dedication to the study and development of autoimmune therapeutics will provide invaluable experience and leadership as we move forward and expand our clinical programs.”

BirchBioMed, a University of British Columbia (UBC) spinoff, holds the exclusive worldwide pharmaceutical license for two medical therapeutic technologies from UBC that hold the promise of being significant medical breakthroughs in the treatment of scarring and certain autoimmune diseases, including type 1 diabetes and alopecia areata.

Their patented anti-scar (FS2) and immunomodulatory (AI-001) technologies have the potential to become life-changing treatments for regenerative medicine.

For more information, visit www.birchbiomed.com.

For further information, contact:

Susan Elliott

Chief Marketing Officer

BirchBioMed Inc.

Phone: (905) 833-0826

susan.elliott@birchbiomed.com

birchbiomed.com

